News | July 24, 2024
Syngene reports drop in Q1 FY25 revenue to Rs. 790 Cr
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Subscribe To Our Newsletter & Stay Updated
